Twist Bioscience Competitors

Bio-Techne (NASDAQ:TECH) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Profitability

This table compares Bio-Techne and Twist Bioscience's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Bio-Techne and Twist Bioscience's gross revenue, earnings per share (EPS) and valuation.

Bio-Techne has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Bio-Techne and Twist Bioscience, as reported by MarketBeat.com.

Bio-Techne presently has a consensus price target of $396.1111, suggesting a potential downside of 6.37%. Twist Bioscience has a consensus price target of $137.50, suggesting a potential upside of 17.78%. Given Twist Bioscience's higher possible upside, analysts clearly believe Twist Bioscience is more favorable than Bio-Techne.

Insider and Institutional Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by insiders. Comparatively, 7.0% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

Bio-Techne beats Twist Bioscience on 11 of the 14 factors compared between the two stocks.

argenx (NASDAQ:ARGX) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Profitability

This table compares argenx and Twist Bioscience's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares argenx and Twist Bioscience's gross revenue, earnings per share (EPS) and valuation.

Twist Bioscience has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for argenx and Twist Bioscience, as reported by MarketBeat.com.

argenx presently has a consensus price target of $292.8750, suggesting a potential upside of 11.06%. Twist Bioscience has a consensus price target of $137.50, suggesting a potential upside of 17.78%. Given Twist Bioscience's higher possible upside, analysts clearly believe Twist Bioscience is more favorable than argenx.

Insider and Institutional Ownership

54.2% of argenx shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 7.0% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

argenx has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Twist Bioscience has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Novavax (NASDAQ:NVAX) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Profitability

This table compares Novavax and Twist Bioscience's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Novavax and Twist Bioscience's gross revenue, earnings per share (EPS) and valuation.

Novavax has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Novavax and Twist Bioscience, as reported by MarketBeat.com.

Novavax presently has a consensus price target of $229.6429, suggesting a potential upside of 30.48%. Twist Bioscience has a consensus price target of $137.50, suggesting a potential upside of 17.78%. Given Novavax's stronger consensus rating and higher possible upside, analysts clearly believe Novavax is more favorable than Twist Bioscience.

Insider and Institutional Ownership

49.9% of Novavax shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 3.3% of Novavax shares are owned by insiders. Comparatively, 7.0% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Novavax has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

QIAGEN (NYSE:QGEN) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for QIAGEN and Twist Bioscience, as reported by MarketBeat.com.

QIAGEN presently has a consensus price target of $60.76, suggesting a potential upside of 27.54%. Twist Bioscience has a consensus price target of $137.50, suggesting a potential upside of 17.78%. Given QIAGEN's stronger consensus rating and higher possible upside, analysts clearly believe QIAGEN is more favorable than Twist Bioscience.

Insider and Institutional Ownership

43.6% of QIAGEN shares are owned by institutional investors. Comparatively, 87.9% of Twist Bioscience shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by insiders. Comparatively, 7.0% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares QIAGEN and Twist Bioscience's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares QIAGEN and Twist Bioscience's gross revenue, earnings per share (EPS) and valuation.

QIAGEN has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

QIAGEN has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Summary

QIAGEN beats Twist Bioscience on 11 of the 14 factors compared between the two stocks.

Twist Bioscience (NASDAQ:TWST) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Twist Bioscience and Repligen, as reported by MarketBeat.com.

Twist Bioscience presently has a consensus target price of $137.50, suggesting a potential upside of 17.78%. Repligen has a consensus target price of $222.75, suggesting a potential upside of 18.61%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Twist Bioscience.

Insider & Institutional Ownership

87.9% of Twist Bioscience shares are held by institutional investors. Comparatively, 84.3% of Repligen shares are held by institutional investors. 7.0% of Twist Bioscience shares are held by insiders. Comparatively, 1.7% of Repligen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Twist Bioscience and Repligen's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Twist Bioscience and Repligen's gross revenue, earnings per share (EPS) and valuation.

Repligen has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Twist Bioscience has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Summary

Repligen beats Twist Bioscience on 11 of the 14 factors compared between the two stocks.

Twist Bioscience (NASDAQ:TWST) and Neurocrine Biosciences (NASDAQ:NBIX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Twist Bioscience and Neurocrine Biosciences, as reported by MarketBeat.com.

Twist Bioscience presently has a consensus target price of $137.50, suggesting a potential upside of 17.78%. Neurocrine Biosciences has a consensus target price of $127.8333, suggesting a potential upside of 40.41%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Neurocrine Biosciences is more favorable than Twist Bioscience.

Insider & Institutional Ownership

87.9% of Twist Bioscience shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 7.0% of Twist Bioscience shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Twist Bioscience and Neurocrine Biosciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Twist Bioscience and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Neurocrine Biosciences has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Twist Bioscience has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.

Summary

Neurocrine Biosciences beats Twist Bioscience on 12 of the 14 factors compared between the two stocks.